The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer.
Amelia Bruce Zelnak
No relevant relationships to disclose
Sujatha Murali
No relevant relationships to disclose
Toncred Marya Styblo
No relevant relationships to disclose
Grant Walter Carlson
No relevant relationships to disclose
Sheryl G. A. Gabram
No relevant relationships to disclose
Monica Rizzo
No relevant relationships to disclose
Mylin Ann Torres
No relevant relationships to disclose
Mary Newell
No relevant relationships to disclose
Yuan Liu
No relevant relationships to disclose
Ruth O'Regan
No relevant relationships to disclose